Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 10/20 | 0.44 |
| ▸ | NPY1R | P25929 | 7/20 | 0.44 |
| ▸ | NPY2R | P49146 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.44 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.43 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.43 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.43 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNG | P07510 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.40 |
| ▸ | CHRND | Q07001 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL1663172 | 1.00 | GRIA1 (0.46) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL15666821 | 0.98 | GRIA1 (0.44) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL13731797 | 0.98 | GRIA1 (0.44) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL15666827 | 0.98 | GRIA1 (0.44) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL15665507 | 0.98 | GRIA1 (0.44) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL15665508 | 0.98 | GRIA1 (0.44) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL15666445 | 0.92 | TRPV1 (0.43) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL13731960 | 0.92 | TRPV1 (0.43) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL15665797 | 0.92 | TRPV1 (0.43) | GRIA1NPY4RNPY1RNPY2RNPY5R | |
| Arginine SCHEMBL15666481 | 0.92 | TRPV1 (0.43) | GRIA1NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10697019-B2 | Method of diagnosis and prognosis | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| EP-3178836-A1 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2017-06-14 | — | — | EP | disclosed |
| EP-2702167-B1 | METHODS OF DIAGNOSIS AND PROGNOSIS OF MULTIPLE MYELOMA, BY MEASURING GADD45BETA EXPRESSION | IMP INNOVATIONS LTD (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-9518083-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | IP2IPO INNOVATIONS LIMITED (GB) | 2015-12-24 | — | — | US | disclosed |
| US-20140128330-A1 | METHOD OF DIAGNOSIS AND PROGNOSIS | IMPERIAL INNOVATIONS LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | GRIA1 3160/4885NPY4R 4859/4885NPY1R 4857/4885 |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | GRIA1 1613/4885NPY4R 2105/4885NPY1R 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.